Genetic Engineering and Biotechnology News has the scoop on a new study the Roskamp Institute is conducting. Here are the details:
SARASOTA, Fla., April 30 /PRNewswire/ — The Roskamp Institute announced today that it is now screening patients for enrollment in a new Phase III study to evaluate the efficacy and safety of FTY720 (fingolimod), a novel, investigational, once-daily, oral medication, in relapsing-remitting multiple sclerosis (RRMS). The 12-month, double-blind, randomized, active-comparator study, called “TRANSFORMS” (TRial Assessing injectable interferoN vS FTY720 Oral in RrMS) is sponsored by Novartis and will include approximately 1275 MS patients in more than 170 study centers worldwide.
“If the Phase III study program confirms the data demonstrated in the Phase II study program and leads to FDA approval, FTY720 may represent an improvement when compared to currently-available injectable medications,” said
Dr. Andrew Keegan, Principal Investigator.